82 results match your criteria: "Shilpa Medical Research Centre[Affiliation]"
Diabetes Res Clin Pract
January 2025
Department of Cardiovascular and Metabolic Diseases, Istituto Ricerca Cura Carattere Scientifico Multimedica, Sesto, San Giovanni (MI), Italy.
Primary prevention of diabetes still remains as an unmet challenge in a real world setting. While, translational programmes have been successful in the developed nations, the prevailing social and economic inequities in the low and middle income countries, fail to integrate diabetes prevention into their public health systems. The resulting exponential increase in the prevalence of diabetes and the cost of treatment has put primary prevention in the back seat.
View Article and Find Full Text PDFJ Assoc Physicians India
December 2024
Medical Affairs, Department of Medical Affairs, Macleods Pharmaceuticals, Mumbai, Maharashtra, India, ORCID: https://orcid.org/0009-0002-2663-4645, Corresponding Author.
India has a high burden of hypertension (HTN), which is often poorly controlled, leading to hypertension-mediated organ damage (HMOD). In the management of HTN, angiotensin receptor blockers (ARBs) assume prime importance, being first-line agents for most patient subgroups. Olmesartan is a highly efficacious ARB that demonstrates sustained blood pressure (BP) reduction over 24 hours.
View Article and Find Full Text PDFJ Assoc Physicians India
November 2024
Department of Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
The prevalence of hypertension is on the rise, with approximately 200 million individuals affected by this condition in India. Epidemiological studies suggest that one in every three adults in India has hypertension. Fixed-dose combinations (FDCs) present a potential strategy to address the challenge of effective blood pressure control.
View Article and Find Full Text PDFJ Assoc Physicians India
November 2024
Consultant Physician and Diabetologist, Department of Medicine, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
The medical community recently endured a heartbreaking tragedy with the brutal rape and murder of a young medical student in Kolkata. The tragic event at R G Kar Medical College in Kolkata is particularly distressing. While the reasons behind it may be complex-whether linked to a drug racket, a personal vendetta, or even the accused's questionable history as a womanizer and porn addict-the fact remains that justice appears elusive.
View Article and Find Full Text PDFJ Assoc Physicians India
October 2024
Medical Lead, Medical Safety Sciences, JNTL Consumer Health (India) Private Limited, Mumbai, Maharashtra, India, Corresponding Author.
J Assoc Physicians India
October 2024
Professor and Director, University of California, Irvine School of Medicine, Irvine, California, United States.
Adverse cardiovascular (CV) events have declined in Western countries due at least in part to aggressive risk factor control, including dyslipidemia management. The American and European (Western) dyslipidemia treatment guidelines have contributed significantly to the reduction in atherosclerotic cardiovascular disease (ASCVD) incidence in the respective populations. However, their direct extrapolation to Indian patients does not seem appropriate for the reasons described below.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Medical Advisor, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
Torsemide, a loop diuretic, is increasingly recognized for its role in managing essential hypertension. Its mechanism of action involves inhibiting the reabsorption of sodium and chloride ions in the ascending loop of Henle in the kidneys. By doing so, torsemide promotes diuresis, which refers to increased urine production, and subsequently lowers blood pressure.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Country Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
Hepatic edema is caused by decreased hepatic protein synthesis, a consequence of decompensated liver cirrhosis. Fluid accumulation occurs when there is an increase in hydrostatic pressure in the hepatic sinusoids and splanchnic capillaries, as well as low albumin. The first-line treatment for cirrhosis-related ascites is an aldosterone antagonist (spironolactone); however, in severe and recurring ascites, a combination of aldosterone antagonists and loop diuretics (torsemide, furosemide, and bumetanide) is preferable.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Cluster Medical Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
Heart failure (HF) is the fastest-growing disease with a higher fatality rate. The most differentiating feature of HF is pulmonary or peripheral edema, which is characterized by a gradient between intravascular and extravascular pressure. Loop diuretics were chosen as the primary treatment for edema associated with HF due to their efficacy and early onset of action.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Country Head; Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
Loop diuretics are regarded as essential for the treatment of edematous conditions in heart failure, cirrhosis, and renal disease. The principal mechanism of action involves inhibiting the reabsorption of ions (Na+, 2Cl-, and K+) from the ascending loop of Henle. The pharmacokinetic (PK) and pharmacodynamic (PD) features of the commonly used diuretics (torsemide, furosemide, and bumetanide) influence the selection of diuretics in various disease states and dosing regimens.
View Article and Find Full Text PDFJ Assoc Physicians India
September 2024
Cluster Medical Head, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.
J Assoc Physicians India
September 2024
Consultant Cardiologist, Medanta Moolchand Heart Centre, Delhi, India.
J Assoc Physicians India
August 2024
Secretary, General Physician, Association of Physicians of India (API), Ajmer, Rajasthan, India.
In India and the Southeast Asian population, hypertension and type 2 diabetes mellitus (T2DM) are the leading lifestyle-related diseases, responsible for a majority burden of morbidity and mortality. Multiple population-spanning studies have revealed the staggering prevalence of both diseases in India, and the prevalence of both will only increase further due to factors such as an aging population, rapid urbanization, increased obesity, and sedentary lifestyles. More than 50 percent of hypertensive patients in India are also diagnosed with T2DM, and a detailed management protocol for the same is required, especially when a major portion of the disease is managed at the primary care level.
View Article and Find Full Text PDFJ Assoc Physicians India
August 2024
Consultant Physician and Diabetes Specialist, Department of Diabetes & Endocrinology, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
Nonarteritic anterior ischemic optic neuropathy (NAION) was first documented by a French physician Jean-Pierre Saint-Yves in 1817 (19th century). The clinical description of NAION was not known until 1935 when C. Miller Fischer thoroughly described it.
View Article and Find Full Text PDFJ Assoc Physicians India
July 2024
Medical Affairs, Macleods Pharmaceuticals, Mumbai, Maharashtra, India.
J Assoc Physicians India
July 2024
Resident, Lilavati Hospital, Mumbai, Maharashtra, India.
Introduction: Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) are linked to the global diabetes epidemic, leading to increased disease progression and adverse health outcomes. The renaming of NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD) at the 2023 European Association for the Study of the Liver Congress highlights the complex relationship between metabolic disorders and liver health. Taking this into consideration, we aimed this study to identify prevalence and risk factors associated with the stages of NAFLD in individuals with T2DM in the Indian population.
View Article and Find Full Text PDFJ Assoc Physicians India
June 2024
Therapy Area Head, Self-Care; Medical Affairs, JNTL Consumer Health (India) Private Limited, Mumbai, Maharashtra, India, Corresponding Author.
J Assoc Physicians India
June 2024
Consultant Physician and Diabetologist, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.
J Assoc Physicians India
June 2024
Consultant and HOD, Department of Endocrine, Lilavati Hospital, Mumbai, Maharashtra, India.
Aim: A retrospective observational study was undertaken to assess the changing trends in the incidence of metabolic syndrome (MetS) in Asian-Indian patients with newly diagnosed type 2 diabetes (T2D) using Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATP III), World Health Organization (WHO), and the International Diabetes Federation (IDF) criteria. The overall and gender-wise pattern of MetS and its components were also evaluated.
Materials And Methods: Newly diagnosed T2D patients ( = 10,950)visiting Dr Panikar's Diabetes Care Centre from 2004 to 2019 with retrievable electronic medical records were selected.
J Assoc Physicians India
May 2024
Consultant Cardiologist, Medanta Moolchand Heart Center, Delhi, India.
Chronic kidney disease (CKD) is a major contributor to morbidity and mortality in India. CKD often coexists with heart failure (HF), diabetes, and hypertension. All these comorbidities are risk factors for renal impairment.
View Article and Find Full Text PDFJ Assoc Physicians India
May 2024
Director, Department of Pulmonology, C K Birla Group of Hospitals, Kolkata, West Bengal, India.
Lung cancer (LC) has the highest rate of disability-adjusted life years (DALY) of all cancers in India. A large majority of patients with LC present with advanced disease, resulting in poor survival rates. Early diagnosis can improve survival outcomes as the patients can be treated with curative intent.
View Article and Find Full Text PDFJ Assoc Physicians India
May 2024
Vice Chairman, Dr Mohan's Diabetes Specialities Centre and Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.
J Assoc Physicians India
April 2024
Dy. Director-Medical Services and Pharmacovigilance, Blue Cross Laboratories Pvt Ltd., Mumbai, Maharashtra, India, Corresponding Author.
Calcium channel blockers (CCBs) are widely used antihypertensive agents due to their effectiveness in reducing blood pressure (BP), along with their good tolerability and evidence of reducing hypertension (HTN)-related cardiovascular and renal diseases. Cilnidipine, a unique dihydropyridine calcium antagonist, exhibits potent inhibitory action on both N-type and L-type voltage-dependent calcium channels. With excellent oral absorption and a prolonged duration of action, it demonstrates a significant antihypertensive effect.
View Article and Find Full Text PDFJ Assoc Physicians India
March 2024
Deputy Director, Department of Medical Services and Pharmacovigilance, Blue Cross Laboratories Private Limited, Mumbai, Maharashtra, India, Corresponding Author.
For >3 decades now, angiotensin receptor blockers (ARB) have been used in the management of hypertension (HTN) and HTN-related cardiovascular (CV) diseases. Olmesartan medoxomil (OLM) is an angiotensin II type 1 (AT1) receptor antagonist (or blocker) that binds tightly to the AT1 receptor with long-lasting efficacy over the 24-hour period and safety demonstrated in several trials. It is well tolerated and effective in reducing blood pressure (BP) in mono and combination therapy with thiazide diuretics or calcium channel blockers across a wide range of patient subgroups.
View Article and Find Full Text PDFJ Assoc Physicians India
March 2024
President, Department of Medical Affairs, Alkem Laboratories Limited, Mumbai, Maharashtra, India.
Antibiotics are the magic bullets that have saved millions worldwide. Enormous and irresponsible use of antibiotics has led to resistance to antibiotics, which is a matter of global health concern. The superbugs are responsible for life-threatening infections, treatment failure, and high mortality worldwide.
View Article and Find Full Text PDF